AVBP Profile
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of novel medicines aimed at addressing unmet medical needs in oncology. The company's core mission is to advance targeted therapies for various forms of cancer, including non-small-cell lung cancer (NSCLC) and other solid tumors.
ArriVent BioPharma's lead therapeutic candidate, Furmonertinib, is an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing Phase 3 clinical trials. This promising therapy is designed to target specific genetic mutations associated with NSCLC, offering a potential new treatment option for patients who have limited alternatives.
In addition to Furmonertinib, the company is advancing other oncology therapies, including ARR-002. ArriVent BioPharma is also engaged in strategic collaborations to bolster its research and development capabilities. Notably, it has partnered with Aarvik Therapeutics Inc., leveraging joint expertise and resources to accelerate the development and commercialization of its targeted cancer treatments.
Founded in 2021 and headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma is dedicated to pioneering innovative solutions in cancer therapy. The company’s commitment to developing targeted treatments and its strategic partnerships position it as a significant player in the biopharmaceutical industry, with a focus on improving patient outcomes in oncology.
|
